VOGXVogenx

US ExchangeHealth Care2026-08-12

Clinical-stage biopharma developing therapeutics for metabolic disorders including post-bariatric hypoglycemia and gastroparesis.

$13IPO price

$82MRaised

$13Day-1 close

75.31%Day-1 return

Clinical-stage biopharma developing therapeutics for metabolic disorders including post-bariatric hypoglycemia and gastroparesis.

Company description (source: StockAnalysis)

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.

医疗健康

51CFO read: CFO must master clinical-stage financial modeling, payer strategy, and FDA regulatory timing.

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.

Talk to us